Gritstone Oncology社、Genedata Biologicsを導入：
Innovative immuno-oncology biotech streamlines discovery of next-generation immunotherapies using Genedata enterprise solution
May 26, 2020
San Francisco, CA, USA
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, including a portfolio of T-cell receptor (TCR)-mimetic bispecific T cell engagers and TCR-based therapeutics, has implemented Genedata Biologics® within their R&D organization.
“Genedata Biologics is a perfect fit for our approach, because it comes with built-in functionalities that support the specialized immuno-oncology applications we require. For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization,” said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology. “We are also looking forward to further automating our R&D processes and increasing throughput in our immunotherapy discovery programs.”
Gritstone Oncology will use Genedata Biologics, a purpose-built enterprise platform for biopharma R&D, to design, engineer, and validate next-generation antibody therapeutic molecules such as bispecific antibodies. Additionally, it will be used for advancing the R&D for multiple programs targeting cancer testis antigens and common mutations resulting in neoantigens. Genedata Biologics integrates all R&D workflows in a common workspace, giving the Gritstone teams comprehensive and real-time access to all relevant R&D data. Using the platform, Gritstone will automate R&D workflows, including molecular biology, screening, engineering, cloning, expression, purification, and analytics processes.
Gritstone Oncology chose to operate Genedata Biologics as Software-as-a-Service (SaaS). This deployment option gives them an agile setup and increases operational efficiency, without the need to invest in the hardware and internal IT support required for an on-premise deployment.
“We are very pleased that Gritstone Oncology, an innovative leader in the field of personalized immunotherapies, has chosen Genedata to support their complex R&D processes,” said Othmar Pfannes, Ph.D., CEO of Genedata. “The Genedata Biopharma Platform is a game changer in biopharma R&D. We help companies stay at the forefront of innovation with our continual investment in developing the platform to address new requirements, such as for TCRs, CAR Ts or novel cancer vaccines. Our goal is to digitalize and streamline all R&D workflows so that our partners can fully exploit the value of their data as they hunt for the next generation of therapies.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.